Search Results - "SATTERLEE, W. G"

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days by O'Rourke, T J, Brown, T D, Havlin, K, Kuhn, J G, Craig, J B, Burris, H A, Satterlee, W G, Tarassoff, P G, Von Hoff, D D

Get more information

Clinical pharmacology of a novel diarylsulfonylurea anticancer agent by Taylor, C W, Alberts, D S, Ketcham, M A, Satterlee, W G, Holdsworth, M T, Plezia, P M, Peng, Y M, McCloskey, T M, Roe, D J, Hamilton, M

“…LY186641 (diarylsulfonylurea, [DSU]) is a novel anticancer agent because of its unique diarylsulfonylurea chemical structure, broad-spectrum antisolid-tumor…”
Get more information

Radiopharmaceutical Treatment of Malignant Pheochromocytoma by Sisson, James C, Shapiro, Brahm, Beierwaltes, William H, Glowniak, Jerry V, Nakajo, Masayuki, Mangner, Thomas J, Carey, James E, Swanson, Dennis P, Copp, Jean E, Satterlee, Winston G, Wieland, Donald M

“…Apart from relieving effects of secreted catecholamines, treatments of malignant pheochromocytoma have achieved little success. When the radiopharmaceutical,…”
Get full text

Phase I clinical study of N-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) by HAINSWORTH, J. D, HANDE, K. R, SATTERLEE, W. G, KUTTESCH, J, JOHNSON, D. H, GRINDEY, G, JACKSON, L. E, GRECO, F. A

“…Between February 1987 and July 1988, 45 patients with advanced refractory cancer were treated with LY186641, a diarylsulfonylurea that has shown a broad…”
Get full text

Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule by Brown, T D, O'Rourke, T J, Kuhn, J G, Craig, J B, Havlin, K, Burris, 3rd, H A, Cagnola, J, Hamilton, J M, Grindey, G B, Satterlee, W G

“…Sulofenur (LY186641), a diarylsulfonylurea, was evaluated clinically utilizing either a daily x 21 schedule or a daily x 5 (with 2 days off) for 3 weeks…”
Get more information

Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule by BUDMAN, D. R, KREIS, W, BEHR, J, SCHULMAN, P, LICHTMAN, S, ALLEN, S. L, WEISELBERG, L, SATTERLEE, W. G, NELSON, R. L, VINCIGUERRA, V

“…Vinzolidine (VZL) is a semisynthetic vinca alkaloid with broad antitumor activity in animal models of malignancy but had unpredictable toxic effects when given…”
Get full text

Dermal uptake of technetium-99m MDP in calcinosis cutis by Larsen, M J, Adcock, K A, Satterlee, W G

“…A rare case of extensive dermal uptake of Tc-99m MDP associated with renal failure is reported. The mechanism of Tc-99m MDP uptake in such examples of…”
Get more information

The effects of fluoxetine on symptoms of insomnia in depressed patients by Satterlee, W G, Faries, D

“…Fluoxetine is an efficacious, nonsedative antidepressant, but its selective efficacy on symptoms of insomnia has not been thoroughly explored. In this…”
Get more information

A phase I and pharmacokinetic study of intravenous vinzolidine by TAYLOR, C. W, SALMON, S. E, SATTERLEE, W. G, ROBERTONE, A. B, MCCLOSKEY, T. M, HOLDSWORTH, M. T, PLEZIA, P. M, ALBERTS, D. S

“…The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days…”
Get full text

The carcinoid syndrome: chronic treatment with para-chlorophenylalanine by Satterlee, W G, Serpick, A, Bianchine, J R

Get more information